The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


GLOBAL LEADERS: looking now at the bigger picture

EuroIntervention 2019;15:e1030-e1032. DOI: 10.4244/EIJV15I12A192

1. Sorbonne Université, ACTION Study Group, INSERM UMRS_1166 Institut de Cardiologie (AP-HP), Paris, France

The issue of the optimal antithrombotic therapy following a percutaneous coronary intervention (PCI) or an acute coronary syndrome has remained a question in modern cardiology, despite many successive breakthroughs. Nearly two decades ago, the Clopidogrel in Unstable Angina to prevent Recurrent Events (CURE) trial demonstrated the superiority of dual antiplatelet therapy, based on aspirin with a P2Y12 inhibitor over aspirin and placebo, in this high-risk population1. Since then, numerous trials have evaluated various strategies of more or less prolonged DAPT duration with more or less potent P2Y12 inhibitors in association with aspirin2. Such strategies have resulted in ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Predicting TMVR outcomes – the Tendyne experience